title: Erythrocyte apheresis in combination with elimination of fibrinogen and plasma proteins of higher molecular weight in macular disease and in uveal effusion syndrome.
abstract: Reduction of hematocrit as well as elimination of fibrinogen and plasma proteins of higher molecular weight are effective approaches in hemorheology. A combination of these therapeutical concepts was applied in one patient with uveal effusion syndrome and in 16 patients with maculopathy. The hematocrit was reduced by erythrocyte apheresis. Fibrinogen and plasma proteins were eliminated by plasma exchange. In the case of uveal effusion syndrome the filling of the scleral veins as well as the uveal effusion were reduced. Furthermore visual function was improved significantly. In 9 of the 16 patients with maculopathy a significant increase in visual acuity occurred. The therapy described lowers significantly the following parameters: hematocrit, fibrinogen, serum proteins, plasma viscosity, erythrocyte aggregation and apparent whole blood viscosity (native and standardized). In a multiple linear regression analysis we found correlations as follows: plasma viscosity correlates with fibrinogen and proteins of higher molecular weight (r = 0.82), erythrocyte aggregation with fibrinogen and proteins of higher molecular weight (r = 0.88), standardized apparent whole blood viscosity with fibrinogen and proteins of higher molecular weight (r = 0.88) and native apparent whole blood viscosity with hematocrit, fibrinogen and proteins of higher molecular weight (r = 0.91).
authors.affiliation: Department of Ophthalmology, University of Cologne, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Brunner
authors.forename: H
authors.initials: H
authors.lastname: Borberg
authors.forename: J
authors.initials: J
authors.lastname: Kadar
authors.forename: M
authors.initials: M
authors.lastname: Heidel
authors.forename: K
authors.initials: K
authors.lastname: Heidner
authors.forename: W
authors.initials: W
authors.lastname: Konen
mesh_terms: D001781:Blood Component Removal / Q000379:methods*; D001783:Blood Flow Velocity / Q000502:physiology; D001798:Blood Proteins / Q000378:metabolism*; D003930:Diabetic Retinopathy / Q000097:blood / Q000628:therapy; D004903:Erythrocyte Aggregation / Q000502:physiology; D017707:Erythrocyte Transfusion; D005340:Fibrinogen / Q000378:metabolism*; D006400:Hematocrit; D006801:Humans; D008266:Macula Lutea / Q000098:blood supply*; D008970:Molecular Weight; D012164:Retinal Diseases / Q000097:blood* / Q000628:therapy*; D012212:Rheology; D014603:Uveal Diseases / Q000097:blood* / Q000628:therapy*
chemical_list: D001798:Blood Proteins; D005340:Fibrinogen